Paul Hudson and Christi Shaw, MBA, are highlighted.

graphic

On September 1, Paul Hudson became CEO of Sanofi, replacing Olivier Brandicourt, MD, PhD, who retired. Most recently, Hudson was the CEO of Novartis Pharmaceuticals and a member of Novartis's executive committee. Hudson also spent 10 years at AstraZeneca, where he held various roles including president of AstraZeneca Japan, president of AstraZeneca U.S., and executive vice president of AstraZeneca North America. He also worked at Schering Plough.

graphic

Christi Shaw, MBA, began her role as CEO of Kite, a subsidiary of Gilead, at the end of August. Previously, Shaw was the senior vice president of Eli Lilly and president of Lilly Bio-Medicines. She will continue to serve on the boards of Avantor, Inc., the Biotechnology Industry Organization, and the Healthcare Businesswomen's Association. Prior to Lilly, Shaw was the U.S. country head and president of Novartis, and the North American head of Novartis Oncology.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.